

Chapter 93

REFERENCES

1. *Annual Report to the Nation on the Status of Cancer, 1975-2006, Featuring Colorectal Cancer Trends and Impact of Interventions (Risk Factors, Screening, and Treatment) to Reduce Future Rates*. Published online December 7, 2009, in *Cancer*. First author: Brenda K. Edwards, PhD, Surveillance Research Program, National Cancer Institute.
2. American Cancer Society. *Cancer Fact and Figures 2009*. Atlanta, GA: American Cancer Society; 2009.
3. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med*. 1994;330(9):592-596.
4. Von Roenn JH, Cleeland CS, Gonin R. Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. *Ann Intern Med*. 1993;119:121-126.
5. World Health Organization. *Cancer Pain Relief and Palliative Care*. 2nd ed. Geneva, Switzerland: World Health Organization; 1996:12-15.
6. Zech DF, Grond S, Lynch J, et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. *Pain*. 1995;63:65-76.
7. Stjernsward J, Colleau SM, Ventafridda V. The World Health Organization Cancer Pain and Palliative Care Program. Past, present, and future. *J Pain Symptom Manage*. 1996;12:65-72.
8. Lillemoe KD, Cameron JL, Kaufman HS, et al. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. *Ann Surg*. 1993;217:447-457.
9. Smith TJ, Coyne PJ, et al. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM). *Ann Oncol*. 2005;16:825-833.
10. Breitbart W. Suicide in the cancer patient. *Oncology*. 1987;1:49-54.
11. Bolund C. Medical and care factors in suicides by cancer patients in Sweden. *J Psychosomat Oncol*. 1985;3:31-52.
12. Daut RL, Cleeland CS, Flannery RC. Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases. *Pain*. 1983;17:197-210.
13. Fishman B, Pasternak S, Wallenstein SL, et al. The Memorial pain assessment card: a valid instrument for the evaluation of cancer pain. *Cancer*. 1987;60:1151-1158.
14. Ger LP, Ho ST, Sun WZ, et al. Validation of the Brief Pain Inventory in a Taiwanese population. *J Pain Symptom Manage*. 1999;18:316-322.
15. Yun YH, Mendoza TR, Heo DS, et al. Development of a cancer pain assessment tool in Korea: a validation study of a Korean version of the brief pain inventory. *Oncology*. 2004;66:439-444.
16. Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain. *Clin J Pain*. 2004;20:308-318.
17. Stanford EA, Chambers CT, Craig KD. The role of developmental factors in predicting young children's use of a self-report scale for pain. *Pain*. 2006;120:16-23.
18. Perkins FM, Kehlet H. Chronic pain as an outcome of surgery. *Anesthesiology*. 2000;93:1123-1133.
19. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. *N Engl J Med*. 1994;330:592-596.
20. Novy D, Berry MP, Palmer JL, et al. Somatic symptoms in patients with chronic non-cancer related and cancer-related pain. *J Pain Symptom Manage*. 2005;29:603-612.
21. Gonzales GR, Elliott KJ, Portenoy RK, et al. The impact of a comprehensive evaluation in the management of cancer pain. *Pain*. 1991;47:141-144.
22. Lindsay TH, Jonas BM, Sevcik MA, et al. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. *Pain*. 2005;119:233-246.
23. Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. *Minerva Anesthesiol*. 2006;72:151-169.
24. van Wilgen CP, Dijkstra PU, van der Laan BF, et al. Morbidity of the neck after head and neck cancer therapy. *Head Neck*. 2004;26:785-791.
25. Tasmuth T, von Smitten K, Hietanen P, et al. Pain and other symptoms after different treatment modalities of breast cancer. *Ann Oncol*. 1995;6:453-459.
26. Rogers ML, Duffy JP. Surgical aspects of chronic post-thoracotomy pain. *Eur J Cardiothorac Surg*. 2000;18:711-716.
27. Borsje S, Bosmans JC, Van Der Schans CP, et al. Phantom pain: a sensitivity analysis. *Disabil Rehabil*. 2004;26:905-910.
28. Robb KA, Williams JE, Duvivier V, et al. A pain management program for chronic cancer-treatment-related pain: a preliminary study. *J Pain*. 2006;7:82-90.

29. Hermann M, Krum H, Ruschitzka F. To the heart of the matter: coxibs, smoking, and cardiovascular risk. *Circulation*. 2005;112:1024-1029.
30. Zech DF, Grond S, Lynch J, et al. Validation of the World Health Organization guidelines for cancer pain relief: a 10-year prospective study. *Pain*. 1995;63:65-76.
31. Rigor BM. Pelvic cancer pain. *J Surg Oncol*. 2000;75:280-300.
32. Paice JA. Mechanisms and management of neuropathic pain in cancer. *J Support Oncol*. 2003;1:107-120.
33. Meuser T, Pietruck C, Radbruch L, et al. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. *Pain*. 2001;93:247-257.
34. Portnoy RK. Inadequate outcome of opioid therapy for cancer pain: influences on practitioners and patients. In: Patt RB, ed. *Cancer Pain*. Philadelphia, PA: JB Lippincott; 1993:119-128.
35. Colleau S, Toranson DE. Fear of addiction: confronting a barrier to cancer pain relief. *Cancer Pain Release*. 1998;113:1-3.
36. Lyss AP, Portenoy RK. Strategies for limiting the side effects of cancer pain therapy. *Semin Oncol*. 1997;24:S128-S133.
37. Ferrante FM, Bedder M, Caplan KA, et al. Practice guidelines for cancer pain management. *Anesthesiology*. 1996;94:1243-1257.
38. Patt RB, Jain S. Therapeutic decision-making for invasive procedures. In: Patt RB, ed. *Cancer Pain*. Philadelphia, PA: JB Lippincott; 1993:275-283.
39. Melzak R, Wall P. Pain mechanisms: a new theory. *Science*. 1965;150:971-979.
40. Patt RB, Cousins MJ. Neurolytic blockade techniques for chronic and cancer pain. In: Cousins MJ, Bridenbaugh PO, eds. *Neural Blockade*. 3rd ed. Philadelphia, PA: JB Lippincott 1999:1007-1061.
41. Ramamurthy S, Wash NE, Scholenfeld LS, et al. Evaluation of neurolytic block using phenol and cryogenic block in management of chronic pain. *J Pain Symptom Manage*. 1989;4:72-75.
42. Swetlow GI, Weingarten B. Alcohol nerve block for pain in malignant disease. *Med J Rec*. 1926;123:728.
43. Politis MJ, Schaumburg HA, Spence PS. Neurotoxicity of selected chemicals. In: Spence PS, ed. *Experimental and Chemical Neurotoxicity*. Baltimore, MD: William & Wilkins; 1980:613.
44. Rumsby MG, Finean JB. The action of organic solvents in the myelin sheath of peripheral nerve tissue. *J Neurochem*. 1966;12:1509.
45. Lipton S. Neurolysis: pharmacology and drug selection. In: Patt RB, ed. *Cancer Pain*. Philadelphia, PA: JB Lippincott; 1993:343-358.
46. Molles JE, Helweg-Larson J, Jacobson E. Histopathological lesions in the sciatic nerve of the rat following perineural application of phenol and alcohol solutions. *Dan Med Bull*. 1969;16:116-119.
47. Coles PG, Thompson GE. The role of neurolytic blocks in the treatment of cancer pain. *Intern Anesth Clin*. 1991;9:93-104.
48. Kline MT. Radiofrequency techniques in clinical practice. In: Waldman SD, ed. *Interventional Pain Management*. Philadelphia: WB Saunders; 1996:243-293.
49. Cheng TM, Cascino TL, Onofrom BM. Comprehensive study of diagnosis and treatment of trigeminal neuralgia secondary to tumors. *Neurology*. 1993;43:2298-2302.
50. Glynn CJ, Lloyd JW, Barnard JD. Cryoanalgesia in management of pain after thoracotomy. *Thorax*. 1980;35:325-327.
51. Bonica JJ, Buckley FP, Morrica G, et al. Neurolytic blockade and hypophysectomy. In: Bonica JJ, ed. *The Management of Pain*. Philadelphia, PA: Lea & Febiger; 1990:1980-2040.
52. Landis S, Murray J, Bolden S. Cancer statistics. *CA Cancer J Clin*. 1999;49:8-10.
53. Vokes EE, Weickselbaum RR, Lippman SM. Medical progress: head and neck cancer. *N Engl J Med*. 1993;328:184-186.
54. Waldman SD. Blockade of Gasserian ganglion. In: Waldman D, ed. *Interventional Pain Management*. New York, NY: WB Saunders; 2001:316-320.
55. Vital JM, Grenier F, Dautheribes M, et al. An anatomic and dynamic study of the greater occipital nerve. *Surg Radiol Anat*. 1989;11:205-210.
56. Pai U, Raj PP. Peripheral nerve blocks: cervical plexus. In: Raj PP, ed. *Handbook of Regional Anesthesia*. New York, NY: Churchill Livingstone; 1985:163-167.
57. Wertheim HM, Rovenstine EA. Cervical plexus block. *N Y S J Med*. 1939;1311-1315.
58. Master RD, Castresana FJ, Castresana MR. Superficial and deep cervical plexus block: technical considerations. *AANS J*. 1995;63:235-243.
59. Landis S, Murray J, Bolden S. Cancer statistics. *CA Cancer J Clin*. 1998;48:6-11.
60. Bonica JJ. Musculoskeletal disorders of the upper limb. In: Bonica JJ, ed. *The Management of Pain*. 2nd ed. Philadelphia, PA: Lea & Febiger; 1990:891-893.
61. Raj PP. Continuous regional analgesia. In: Raj PP, ed. *Practical Management of Pain*. 3rd ed. St. Louis, MO: Mosby; 2000: 710-722.
62. Moore DC. Intercostal nerve block in 4333 patients: indications, techniques, and complications. *Anesth Analg*. 1962;41:1-10.
63. Kopacz DJ, Thompson GE. Intercostal nerve block. In: Waldman SD, ed. *Interventional Pain Management*. 2nd ed. St. Louis, MO: WB Saunders; 2001:401-407.
64. Conacher ID. Percutaneous cryotherapy for post thoracotomy neuralgia. *Pain*. 1986;25:227-230.
65. Debacker LJ, Kienzle WK, Keasley HH. A study of stellate ganglion block for pain relief. *Anesthesiology*. 1959;20: 618-625.
66. Bonica JJ. Autonomic innervation of viscera in relation to nerve block. *Anesthesiology*. 1968;29:793-795.
67. Plancarte R, Velaquez R, Patt RB. Neurolytic blocks of the sympathetic axis. In: Patt RB, ed. *Cancer Pain*. Philadelphia, PA: JB Lippincott; 1993:377-425.
68. Brown DL, Bulley CK, Quiel EL. Neurolytic celiac plexus block for pancreatic cancer pain. *Anesth Analg*. 1987;66: 869-873.
69. Plancarte R, Amescua C, Patt RB, et al. Superior hypogastric block for pelvic cancer pain. *Anesthesiology*. 1990;73:236-240.
70. Warfield CA, Crews DA. Use of stellate ganglion blocks in treatment of intractable limb pain in lung cancer. *Clin J Pain*. 1987;3:13-15.
71. Racz GB, Holubec JT. Stellate ganglion phenol lysis. In: Racz GB, ed. *Techniques of Neurolysis*. Boston, MA: Kluwer Academic; 1989:133-140.
72. Thompson GE, Moore DC, Bridenbaugh PO, et al. Abdominal pain and celiac plexus nerve block. *Anesth Analg*. 1977;56:1-3.
73. Reber HA, Foley KM. Pancreatic cancer pain: presentation, pathogenesis, and management. *J Pain Symptom Manage*. 1988;3:163-176.

74. Labat G. Splanchnic analgesia. In: Labat G, ed. *Regional Anesthesia: Its Techniques and Clinical Application*. Philadelphia, PA: WB Saunders; 1928:398-402.
75. Moore DC, Bush WH, Barnett LL. Celiac plexus block: a roentgenographic, anatomic study of techniques and spread of solution in patients and corpses. *Anesth Analg*. 1981;60:369-375.
76. Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus blockade for treatment of cancer pain: a metaanalysis. *Anesth Analg*. 1995;80:290-307.
77. Boas RA. Sympathetic blocks in clinical practice. *Int Anesthesiol Clin*. 1978;16:149-155.
78. Reid W, Watt JK, Gray TG. Phenol injection of sympathetic chain. *Br J Surg*. 1970;57:45-50.
79. Frier A. Pelvic neurectomy in gynecology. *Obstet Gynecol*. 1965;25:48.
80. Lee RB, Stone K, Magelssen D, et al. Presacral neurotomy for chronic pelvic pain. *Obstet Gynecol*. 1986;68:517-521.
81. Plancarte R, Amesca C, Patt RB, et al. Superior hypogastric plexus block for pelvic cancer pain. *Anesthesiology*. 1990;73:236.
82. Plancarte R, Amesca C, Patt RB, et al. Presacral blockade of the ganglion of Walther (ganglion impar). *Anesthesiology*. 1990;73:A751.
83. Lubenow T, Ivankovich A. Intraspinal narcotics for treatment of cancer pain. *Semin Surg Oncology*. 1990;6:173.
84. Dupen SL, Williams AR. Spinal and peripheral drug delivery systems. *Pain Digest*. 1995;5:307-317.
85. Burton AW, Rajagopal A, Shah HN, et al. Epidural and intrathecal analgesia is effective in treating refractory cancer pain. *Pain Med*. 2004;5:239-247.
86. Bedler MD, Burchil K, Larson A. Cost analysis of two implantable narcotic delivery systems. *J Pain Symptom Manage*. 1991;6:368.
87. Hassenbusch SJ, Paice JA, Patt RB, et al. Clinical realities and economic considerations: economic of intrathecal therapy. *J Pain Symptom Manage*. 1997;14:536-548.
88. Burton AW, Reddy SK, Shah HN, et al. Percutaneous vertebroplasty—a technique to treat refractory spinal pain in the setting of advanced metastatic cancer: a case series. *J Pain Symptom Manage*. 2005;30:87-95.
89. Cotton A. Percutaneous vertebroplasty for osteolytic metastases and myeloma: effects of the percentage of lesion filling and the leakage of methylmethacrylate at clinical followup. *Radiology*. 1996;200:525-530.
90. Burton AW, Hamid B. Kyphoplasty and vertebroplasty. *Curr Pain Headache Rep*. 2008;12(1):22-27.
91. Field MJ, Behrman RE, eds. *When Children Die: Improving Palliative and End-of-Life Care for Children and Their Families*. Washington, DC: National Academy Press; 2003.
92. Foley KM, Gelband H, eds. *Improving Palliative Care for Cancer*. Washington DC: National Academy Press; 2001.